MS-275

10 mg

Cat. No.: 92-Y43

$69.00

MS-275 is a potent HDAC inhibitor with an IC50 of 0.3 and 8µM for HDAC1 and HDAC3. It has been shown to inhibit tumor growth by inducing tumor suppressors p21WAF1/CIP1 and gelsolin through the acetylation of histones and changing cell cycle distribution. MS-275 has been shown to exert dose-dependent effects in human leukemia cells at low concentrations in human prostate cancer lines. MS-275 inhibits proliferation of various human tumor cell lines and inhibits the growth of human tumor xenographs in the nude mouse.

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: MS-27-275, MS 275-27, Histone Deacetylase Inhibitor I, SNDX-275, Entinostat

Chemical Formula: C21H20N4O3

CAS Number: 209783-80-2

Molecular Weight: 376.41

Purity:  >98%

Appearance:  a crystalline solid  

Solubility: DMSO

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO at 25 mg/ml with slight warming. If precipitate is observed,  vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

References

Saito et al. (1999) A synthetic inhibitor of histone deacetylase | MS-27-275 | with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96(8):4592-7.

Lee et al. (2001) MS-275 | a histone deacetylase inhibitor | selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res. 61(3):931-34.

Kato et al. (2007) Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 13(15):4538-46.

Tech Docs

Product Specifications

MSDS